Bay Area Biotech
Life Sciences

Mirati Therapeutics: Investing In A Piece Of The Precision Medicine Pie

By Evangelos Pazarentzos, Ph.D., Merce Padro, Ph.D., Joan Zape, Srijib Goswami, and Gorjan Hrustanovic

Mirati Therapeutics (NASDAQ:MRTX) is a development-stage biotechnology company focusing on the development of targeted small-molecule inhibitors for the treatment of solid and hematological cancers. As of December 2013, Mirati had 62.1M cash and is burning ~$11.2M/qtr. As of writing, Mirati is valued at $218M with shares trading at $16.35.

Mirati began trading on NASDAQ in June 2013 after its reincorporation and restructuring from Methylgene, and has since been largely out of the radar of many retail biotech investors. This likely due to Methylgene's previous clinical failures, most famously with the anti-fungal program MGCD290. Since then, Methylgene (now Mirati) has completely reshuffled and revitalized its...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details